Lumos Diagnostics Broadens Henry Schein Distribution Partnership for FebriDx

Lumos Diagnostics (ASX: LDX), a pioneer in rapid point-of-care (POC) diagnostic technologies, has partnered with Henry Schein B.V. to extend the distribution of the FebriDx® POC test in the Netherlands. FebriDx® enables swift differentiation between viral and bacterial acute respiratory infections, providing results within 10 minutes from a fingerstick blood sample.

This advancement supports efficient management of infectious patients in various healthcare settings, including Primary Care, Urgent Care, Emergency Departments, Paediatrics, and Outpatient facilities. Henry Schein B.V., a division of Henry Schein, Inc. (Nasdaq: HSIC), the world's leading provider of healthcare solutions for dental and medical practitioners, will introduce FebriDx to their Medical customers across the Netherlands, with immediate commencement of sales and marketing endeavours.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com